Evaluation of Periostat for patient management.
The cause of adult periodontitis involves complex bacteria-host interactions, with modifying influences exerted by genetic and environmental factors. Current thinking indicates that successful, long-term management of adult periodontitis requires a treatment approach that takes into account the various etiologic components of the disease. Recently, a formulation containing a subantimicrobial dose of doxycycline (Periostat) was approved for use as an adjunct to scaling and root planing (SRP) in the treatment of adult periodontitis. As an inhibitor of matrix metalloproteinases that have been implicated in the pathologic degradation of connective tissue collagen in periodontal support structures, Periostat in conjunction with SRP was shown to significantly improve clinical attachment and reduce probing depth compared with placebo in conjunction with SRP. This article reviews the clinical trial results leading to US Food and Drug Administration approved of Periostat and discusses the potential use of this host-modulatory agent as a complementary systemic pharmacotherapy in periodontal management programs.
Caton
J G
JG
University of Rochester, Eastman Dental Center, New York, USA.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D012534:Dental Scaling; D004318:Doxycycline / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D017622:Periodontal Attachment Loss / Q000188:drug therapy; D010514:Periodontal Pocket / Q000188:drug therapy; D010518:Periodontitis / Q000188:drug therapy* / Q000201:enzymology; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D061965:Matrix Metalloproteinase Inhibitors; D004318:Doxycycline